01
Auto Immune Small Molecule
Phase 1b · Phase 2 planned
Phase 1b · Phase 2 planned
Next: Phase 2
THERAPEUTIC PIPELINE
Advancing breakthrough GPCR science toward patients.
Our internal programs focus on immune, metabolic and pain indications with clear unmet need.
03 / 06
Our Pipelines
Mechanism-led, computation-accelerated, experimentally closed-loop.
AlphaMol Science AlphaMol Science advances several "first-in-class" in-house drug discovery projects. The pipelines include dual functional anti-cancer drug,infections, less side effect painkiller, cancer and metabolism.
AlphaMol With the advantages of outstanding GPCR-oriented drug discovery platform in AlphaMol, we managed to speed up the "first-in-class" preclinical drug discovery processes in an ultimately efficient way. The first-in-class lead compounds and PCC molecules are invented within few months. It saves 80-99% costs in both time and finance.
PROGRAM PROGRESS
A portfolio moving from discovery into clinical development.
02
Metabolism Oral Small Molecule
Preclinical
Preclinical
03
Non-Opioid Painkiller
Preclinical
Preclinical
04
Metabolism Peptide
Lead Optimization
Lead Optimization
The stage map communicates development maturity, not dates or percentage completion.
TRANSLATIONAL PATH
Every stage advances through testable evidence.
Structural and mechanistic insight creates a molecular hypothesis; computational design narrows chemical space; experimental data informs the next cycle.
THERAPEUTIC FOCUS
High-value biology. Differentiated therapeutic opportunities.
Immunology & inflammation
Oral small-molecule therapies targeting mast-cell and immune-regulatory GPCR pathways.
Metabolic disease
Emerging receptor biology involved in metabolic homeostasis and energy regulation.
Pain
Exploring non-opioid mechanisms for potentially safer pain medicines.